<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-58888" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pembrolizumab</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Flynn</surname>
            <given-names>James P.</given-names>
          </name>
          <aff>California Northstate University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gerriets</surname>
            <given-names>Valerie</given-names>
          </name>
          <aff>California Northstate University College of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>James Flynn declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Valerie Gerriets declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-58888.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Pembrolizumab is a medication used in the management and treatment of various oncologic conditions. It is in the cancer immunotherapy class of drugs. This activity will highlight pembrolizumab's mechanism of action, indications, adverse event profile, and other key factors (e.g., non-approved indications currently in clinical trials, administration, dosing, monitoring, and relevant interactions) pertinent for members of the interprofessional team in the management of patients with advanced cancers.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for pembrolizumab.</p></list-item><list-item><p>Summarize the mechanism of action pembrolizumab.</p></list-item><list-item><p>Explain the importance of monitoring for patients on pembrolizumab, including immune-mediated adverse events.</p></list-item><list-item><p>Outline the importance of collaboration and coordination among the interprofessional team when dosing and monitoring pembrolizumab immunotherapy to improve patient outcomes with advanced cancers.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=58888&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=58888">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-58888.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Pembrolizumab is an FDA-approved monoclonal antibody directed against programmed cell death protein 1 (PD-1) and sold in the US. It initially received FDA accelerated approval for refractory, advanced melanoma in September 2014. Subsequently, it has received approval for the treatment of many other oncologic conditions, and many more are currently in clinical development.</p>
        <p>
<bold>FDA-approved indications (with clinical trial summaries)</bold>
</p>
        <p>
<bold>Melanoma</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Unresectable or metastatic melanoma
<list list-type="bullet"><list-item><p>In an advanced melanoma population naive to ipilimumab therapy, median overall survival was not reached in two different pembrolizumab doses (every two weeks, every three weeks dosing) as compared to ipilimumab alone at 16.0 months (hazard ratio = 0.68, p&#x0003c;0.001) at a median follow-up of 22.9 months.<xref ref-type="bibr" rid="article-58888.r1">[1]</xref></p></list-item><list-item><p>In previously treated, ipilimumab refractory, advanced melanoma, treatment with pembrolizumab resulted in overall survival of 13.4 months (2 mg/kg dose) and 14.7 months (10 mg/kg dose) as compared to investigator choice chemotherapy at 11.0 months (results were not statistically significant) at a median follow-up of 28 months.<xref ref-type="bibr" rid="article-58888.r2">[2]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Adjuvant therapy following complete resection of lymph node involved melanoma.
<list list-type="bullet"><list-item><p>In patients with completely resected stage III melanoma, pembrolizumab showed a recurrence-free survival of 75.4% vs. placebo of 61.0% (hazard ratio=0.57, p&#x0003c;0.001) at a median follow-up of 15 months.<xref ref-type="bibr" rid="article-58888.r3">[3]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Non-Small Cell Lung Cancer (NSCLC)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>First-line metastatic non-squamous NSCLC without EGFR/ALK tumor abnormality in combination with platinum chemotherapy and pemetrexed.
<list list-type="bullet"><list-item><p>In patients with metastatic non-squamous NSCLC, first-line treatment of pembrolizumab plus chemotherapy (pemetrexed and carboplatin or cisplatin) showed a median progression-free survival of 8.8 months as compared to 4.9 months from chemotherapy alone (p&#x0003c;0.001) with a median follow up of 10.5 months.<xref ref-type="bibr" rid="article-58888.r4">[4]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>First-line metastatic squamous NSCLC with paclitaxel (or paclitaxel protein-bound) and carboplatin
<list list-type="bullet"><list-item><p>In patients with metastatic squamous NSCLC, first-line treatment of pembrolizumab plus chemotherapy (carboplatin plus paclitaxel or nanoparticle albumin-bound paclitaxel) showed a median overall survival of 15.9 months as compared to 11.3 months for chemotherapy alone (p&#x0003c;0.001) with a median follow up of 7.8 months.<xref ref-type="bibr" rid="article-58888.r5">[5]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>First-line single-agent use for nonresectable or metastatic NSCLC without EGFR/ALK tumor abnormality with tumor PD-L1 expression greater than 1%.
<list list-type="bullet"><list-item><p>In patients with previously untreated advanced NSCLC with a PD-1 score greater than 50%, first-line treatment of single-agent pembrolizumab showed a median overall survival of 30.0 months as compared to chemotherapy (investigator&#x02019;s choice platinum-based regimen) control arm of 14.2 months(hazard ratio = 0.63), with a median follow up of 25.2 months.<xref ref-type="bibr" rid="article-58888.r6">[6]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Single-agent use for metastatic NSCLC with tumor PD-L1 expression greater than 1% who have progressed after platinum-based chemotherapy. (EGFR/ALK tumor abnormality patients with progression after targeted therapy for their respective tumor abnormality).
<list list-type="bullet"><list-item><p>In patients with previously treated, advanced NSCLC with a PD-1 score greater than 50%, subsequent treatment with pembrolizumab (10mg/kg) showed a median survival of 17.3 months as compared to the docetaxel arm of 8.2 months (p&#x0003c;0.0001).<xref ref-type="bibr" rid="article-58888.r7">[7]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Head and Neck Squamous Cell Carcinoma (HNSCC)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>First-line metastatic or unresectable/recurrent HNSCC in combination with FU and platinum.
<list list-type="bullet"><list-item><p>In patients previously untreated for locally incurable recurrent or metastatic head and neck cancer, treatment with pembrolizumab plus chemotherapy (cisplatin or carboplatin/5-FU) resulted in median overall survival of 13.0 months as compared to cetuximab plus chemotherapy(cisplatin or carboplatin/5-FU) of 10.7 months.<xref ref-type="bibr" rid="article-58888.r8">[8]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>First-line single-agent use in metastatic or unresectable/recurrent HNSCC with tumor PD-L1 expression greater than 1%.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Single-agent recurrent or metastatic HNSCC with progression after platinum-based chemotherapy
<list list-type="bullet"><list-item><p>In patients with previously treated advanced head and neck squamous cell carcinoma, a single-arm study showed that treatment with pembrolizumab resulted in an 18% objective response rate; overall survival was 38% at 12 months (after a median follow up of 9 months).<xref ref-type="bibr" rid="article-58888.r9">[9]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Renal Cell Carcinoma (RCC)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>First-line advanced RCC in combination with axitinib
<list list-type="bullet"><list-item><p>In patients previously untreated for advanced clear-cell renal cell carcinoma, treatment with pembrolizumab plus axitinib resulted in a 12-month survival rate of 89.9% compared to treatment with sunitinib at 78.3% (p&#x0003c;0.0001) at a median follow-up of 12.8 months.<xref ref-type="bibr" rid="article-58888.r10">[10]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Urothelial Carcinoma</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Locally advanced or metastatic urothelial carcinoma who have progressed on platinum-based chemotherapy</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Locally advanced or metastatic urothelial carcinoma within 12 months of neoadjuvant/adjuvant platinum-based chemotherapy.
<list list-type="bullet"><list-item><p>In patients with previously treated advanced urothelial cancer, treatment with pembrolizumab resulted in a median one-year survival rate of 44.2% compared to 29.8% for chemotherapy (paclitaxel or docetaxel or vinflunine) alone. The median two-year survival rate was 26.9% for pembrolizumab compared to 11.0% for chemotherapy alone (at a median follow-up of 27.7 months).<xref ref-type="bibr" rid="article-58888.r11">[11]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>FDA-approved indications under accelerated approval (with clinical trial summaries):</bold>
</p>
        <p>
<bold>Classical Hodgkin Lymphoma (cHL)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Refractory cHL for pediatric and adult patients who have relapsed after three or more treatments
<list list-type="bullet"><list-item><p>In patients with relapsed/refractory classical Hodgkin lymphoma, pembrolizumab monotherapy resulted in a 69.9% objective response rate and a complete response rate of 22.5% at a median follow-up of 13 treatment cycles.<xref ref-type="bibr" rid="article-58888.r12">[12]</xref>&#x000a0;&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Primary Mediastinal Large B-Cell Lymphoma (PMBCL)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Refractory PMBCL for pediatric and adults who have relapsed after two or more treatments
<list list-type="bullet"><list-item><p>In patients with relapsed/refractory Primary Mediastinal Large B-cell lymphoma, pembrolizumab treatment resulted in a&#x000a0;41% objective response rate and a 12-month overall survival rate of 62% after a median follow-up of 6.6 months.<xref ref-type="bibr" rid="article-58888.r13">[13]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>&#x000a0;Urothelial Carcinoma</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Locally advanced or metastatic urothelial carcinoma with tumor expression PD-L1 of greater than 10%, ineligible for cisplatin-containing chemotherapy.
<list list-type="bullet"><list-item><p>In patients with advanced urothelial carcinoma who were ineligible for cisplatin, treatment with pembrolizumab resulted in a 29% objective response rate and a median follow-up of 7.8 months.<xref ref-type="bibr" rid="article-58888.r14">[14]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Locally advanced or metastatic urothelial carcinoma not eligible for any platinum-based chemotherapy</p>
          </list-item>
        </list>
        <p>
<bold>Microsatellite Instability-High (MSI-H) Cancer</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Previously treated adult and pediatric unresectable or metastatic MSI-H solid tumors with no remaining alternative treatments.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Adult and pediatric unresectable or metastatic MSI-H colorectal cancer following treatment with irinotecan, oxaliplatin, and fluoropyrimidine
<list list-type="bullet"><list-item><p>In patients with previously treated microsatellite instability-high colorectal cancer, treatment with pembrolizumab resulted in a 32% objective response rate, a 4.1 month PFS and a 76% 12-month overall survival rate after a median follow-up of 12.6 months.<xref ref-type="bibr" rid="article-58888.r15">[15]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Gastric Cancer</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Locally advanced, metastatic gastric or gastroesophageal junction adenocarcinoma with tumor PD-L1 expression greater than 1% with disease progression after at least two lines of therapy, including platinum or fluoropyrimidine chemotherapy (and HER2/neu targeted therapy, if appropriate)
<list list-type="bullet"><list-item><p>In patients with previously treated gastric and gastroesophageal junction cancer, treatment with pembrolizumab resulted in an 11.6% objective response rate at a median follow-up of 5.8 months.<xref ref-type="bibr" rid="article-58888.r16">[16]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Cervical Cancer</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Metastatic or recurrent cervical cancer, following chemotherapy, with tumor expression of PD-L1 greater than 1%.
<list list-type="bullet"><list-item><p>In patients previously treated for advanced cervical cancer, treatment with pembrolizumab resulted in an objective response rate of 12.2% at a median follow-up of 10.2 months.<xref ref-type="bibr" rid="article-58888.r17">[17]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Hepatocellular Carcinoma (HCC)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>HCC patients previously treated with sorafenib
<list list-type="bullet"><list-item><p>In patients with previously treated hepatocellular carcinoma, treatment with pembrolizumab resulted in an objective response rate of 18% at a data cutoff of February 2018.<xref ref-type="bibr" rid="article-58888.r18">[18]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Merkel Cell Carcinoma (MCC)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Pediatric and adult recurrent or locally advanced MCC.
<list list-type="bullet"><list-item><p>In patients naive to systemic treatment for advanced Merkel cell carcinoma, treatment with pembrolizumab resulted in an objective response rate of 56% and 24-month overall survival of 68.7% at a median follow-up of 14.9 months.<xref ref-type="bibr" rid="article-58888.r19">[19]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Small Cell Lung Cancer (SCLC)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Metastatic SCLC following platinum-based chemotherapy and at least one other therapy
<list list-type="bullet"><list-item><p>In patients with previously treated advanced small cell lung cancer, treatment with pembrolizumab resulted in an 18.7% objective response rate and a median overall survival of 9.1months.<xref ref-type="bibr" rid="article-58888.r20">[20]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Non-FDA approved indications in later-stage clinical trials</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Nasopharyngeal cancer</p>
          </list-item>
          <list-item>
            <p>Mesothelioma</p>
          </list-item>
          <list-item>
            <p>Liver cancer</p>
          </list-item>
          <list-item>
            <p>Esophageal cancer</p>
          </list-item>
          <list-item>
            <p>Cutaneous squamous cell carcinoma</p>
          </list-item>
          <list-item>
            <p>Colorectal cancer</p>
          </list-item>
          <list-item>
            <p>Breast cancer</p>
          </list-item>
          <list-item>
            <p>Prostate cancer</p>
          </list-item>
          <list-item>
            <p>Ovarian cancer</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-58888.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Pembrolizumab is a humanized monoclonal IgG4 kappa antibody directed against&#x000a0;human cell surface PD-1 (programmed death receptor-1) on lymphocytes. The PD-1 receptor provides an important &#x0201c;immune checkpoint,&#x0201d; which helps prevent the immune system from attacking itself.<xref ref-type="bibr" rid="article-58888.r21">[21]</xref>&#x000a0;Certain types of tumors have a high expression of PD-L1(programmed death receptor ligand-1).<xref ref-type="bibr" rid="article-58888.r22">[22]</xref> Other tumor types use adaptive immune resistance where they take the natural physiology of PD-L1 induction (protection of immune-mediated damage from infections) and adapt it towards anti-tumor responses.<xref ref-type="bibr" rid="article-58888.r23">[23]</xref> When PD-L1 engages with PD-1, the T-cell function becomes inhibited; pembrolizumab blocks the PD-1: PDL-1 complex formation allowing improved T-cell mediated killing.<xref ref-type="bibr" rid="article-58888.r23">[23]</xref><xref ref-type="bibr" rid="article-58888.r24">[24]</xref></p>
      </sec>
      <sec id="article-58888.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Pembrolizumab is FDA-approved for intravenous use. It comes in either a 50 mg lyophilized powder for reconstitution or a 25 mg/mL solution. &#x000a0;The most common administration schedule is a 200 mg infusion given over 30 minutes every three weeks. Most monoclonal antibodies are dosed based on body size; however, studies have shown that pembrolizumab fixed-dosing provides adequate coverage and yields the advantage of reduced dosage errors, convenience, and less waste (for an expensive therapy).<xref ref-type="bibr" rid="article-58888.r25">[25]</xref> For adverse events, withholding or discontinuing is recommended; dose reductions are not. The drug should be administered within 6 hours from the reconstitution time (24 hours if refrigerated) to minimize the chances of microbial growth.</p>
      </sec>
      <sec id="article-58888.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Clinically significant adverse reactions include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Immune-mediated skin adverse reactions (exfoliative dermatitis, bullous pemphigoid, Stevens-Johnson syndrome, and toxic epidermal necrolysis)</p>
          </list-item>
          <list-item>
            <p>Immune-mediated endocrinopathies (thyroid disorders, type 1 diabetes, hypophysitis)</p>
          </list-item>
          <list-item>
            <p>Immune-mediated colitis</p>
          </list-item>
          <list-item>
            <p>Immune-mediated pneumonitis</p>
          </list-item>
          <list-item>
            <p>Immune-mediated hepatotoxicity/hepatitis</p>
          </list-item>
          <list-item>
            <p>Immune-mediated renal dysfunction and nephritis</p>
          </list-item>
          <list-item>
            <p>Infusion-related reactions (anaphylaxis and hypersensitivity)</p>
          </list-item>
          <list-item>
            <p>Other immune-mediated adverse reactions (Guillain-Barre syndrome, uveitis, myasthenia gravis, pancreatitis, sarcoidosis, vasculitis, hemolytic anemia, arthritis, myositis, and encephalitis)</p>
          </list-item>
        </list>
        <p>Common Side effects that occurred in over 10% of clinical trial participants include:<xref ref-type="bibr" rid="article-58888.r13">[13]</xref><xref ref-type="bibr" rid="article-58888.r14">[14]</xref><xref ref-type="bibr" rid="article-58888.r17">[17]</xref><xref ref-type="bibr" rid="article-58888.r26">[26]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Nervous system (headache)</p>
          </list-item>
          <list-item>
            <p>Musculoskeletal (back pain, arthralgia)</p>
          </list-item>
          <list-item>
            <p>Skin (vitiligo, rash, pruritus)</p>
          </list-item>
          <list-item>
            <p>Metabolism (decreased appetite, weight loss, hyponatremia)</p>
          </list-item>
          <list-item>
            <p>Respiratory (cough, dyspnea)</p>
          </list-item>
          <list-item>
            <p>General (fatigue, pyrexia, asthenia, influenza-like illness, peripheral edema</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal (diarrhea, constipation, abdominal pain, nausea, vomiting)</p>
          </list-item>
          <list-item>
            <p>Endocrine (hypothyroidism, hyperthyroidism)</p>
          </list-item>
          <list-item>
            <p>Infections (pneumonia, urinary tract infection, upper respiratory tract infection)</p>
          </list-item>
          <list-item>
            <p>Cardiac (arrhythmias)</p>
          </list-item>
          <list-item>
            <p>Blood/lymphatic (anemia)</p>
          </list-item>
          <list-item>
            <p>Hepatobiliary (hepatoxicity, elevated liver function tests)</p>
          </list-item>
          <list-item>
            <p>Renal and urinary (hematuria, increase blood creatinine)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-58888.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There are no contraindications for pembrolizumab.</p>
        <p>Limitations of use:</p>
        <list list-type="bullet">
          <list-item>
            <p>Pembrolizumab is not recommended in PMBCL (primary mediastinal large B-cell lymphoma) patients who require urgent cytoreductive therapy.</p>
          </list-item>
          <list-item>
            <p>Pembrolizumab&#x02019;s safety and effectiveness in MSI-H central nervous system pediatric cancer have not been established as this population met the exclusion criteria from clinical trials.<xref ref-type="bibr" rid="article-58888.r27">[27]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-58888.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <list list-type="bullet">
          <list-item>
            <p>Monitor for signs and symptoms of colitis, pneumonitis, hypophysitis, and suspected severe skin reactions.</p>
          </list-item>
          <list-item>
            <p>Monitor for renal function changes as a sign of immune-mediated nephritis.</p>
          </list-item>
          <list-item>
            <p>Monitor for liver function changes as a sign of immune-mediated hepatitis.</p>
          </list-item>
          <list-item>
            <p>Monitor for thyroid function changes as a sign of a thyroid disorder.</p>
          </list-item>
          <list-item>
            <p>Monitor for infusion reactions such as chills, fever, flushing, hypotension, hypoxemia, pruritis, rash, rigors, and wheezing. While checkpoint inhibitors have lower rates of infusion reaction than other monoclonal antibodies, it is still important to monitor.<xref ref-type="bibr" rid="article-58888.r28">[28]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Monitor for hyperglycemia as a sign of type-1 diabetics.</p>
          </list-item>
          <list-item>
            <p>Monitor for hepatic function changes when given in combination with axitinib as a sign of hepatotoxicity. In one study, alanine aminotransferase and aspartate aminotransferase increased by over 25% of pembrolizumab plus axitinib-treated patients.<xref ref-type="bibr" rid="article-58888.r10">[10]</xref>&#x000a0; &#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-58888.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <list list-type="bullet">
          <list-item>
            <p>Pembrolizumab has the potential to cause fetal harm.<xref ref-type="bibr" rid="article-58888.r29">[29]</xref> Females with the ability to become pregnant should receive counseling regarding the risks of fetal injury and using effective contraception.</p>
          </list-item>
          <list-item>
            <p>Animal studies have shown increased severity in certain types of infections, including <italic toggle="yes">M.&#x000a0;tuberculosis</italic>, lymphocytic choriomeningitis virus, and hepatitis B virus.</p>
          </list-item>
          <list-item>
            <p>Pembrolizumab has not been the subject of testing for potential carcinogenicity or genotoxicity.</p>
          </list-item>
          <list-item>
            <p>Pembrolizumab has an elimination terminal half-life of 27 days.<xref ref-type="bibr" rid="article-58888.r30">[30]</xref>&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-58888.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Pembrolizumab is a relatively new biological agent, and even though it is effective, it does require close monitoring for safety; thus, besides the clinician who prescribes the agent, both the nurse and pharmacist are responsible for educating the patient on the potential side effects of the drug. Since some of the adverse effects are delayed-onset like colitis and hypophysitis, an outpatient oncology nurse should follow the patients. The clinician, nurse, and pharmacist team members should regularly check the renal and liver function. During IV administration, the drug is known to cause chills, fever, flushing, hypotension, hypoxemia, pruritis, rash, rigors, and wheezing. While checkpoint inhibitors have lower rates of infusion reaction than other monoclonal antibodies, it is still essential to monitor. More crucially, the drug may cause transient increases in blood glucose. Finally, because the drug can trigger an allergic reaction, the interprofessional team needs to have the necessary medications and equipment to counter it in the room.</p>
        <p>
<bold>Outcomes</bold>
</p>
        <p>PD-L1 expression levels and treatment decision-making in NSCLC (Level 1). &#x000a0;</p>
        <p>Tumor-expressed PD-L1 has the potential to suppress immune system responses by downregulating anti-tumor lymphocyte activity upon binding PD-1. In theory, an antibody that can block this interaction should be an effective anti-cancer agent. In practice, clinical trials of pembrolizumab and other checkpoint inhibitors have shown meaningful responses in many oncology indications thus far. As a corollary, it would make sense that tumors that express the most PD-L1 would be the most susceptible to one of these antibodies.<xref ref-type="bibr" rid="article-58888.r31">[31]</xref> However, tumors that highly express PD-L1 would also be expected to evade the host&#x02019;s immune system better, resulting in a worse prognosis.<xref ref-type="bibr" rid="article-58888.r32">[32]</xref> Therefore, it is difficult to know who will benefit most from these new checkpoint inhibitors, such as pembrolizumab, based on levels of PD-L1 expression.</p>
        <p>In NSCLC, for example, Brody et al. conducted a large meta-analysis of thirty-five different clinical trials and showed many studies that linked higher PD-L1 expression with worse survival, but also several other studies that showed no such effect.<xref ref-type="bibr" rid="article-58888.r33">[33]</xref>&#x000a0;Additionally, PD-L1 as a predictive biomarker for checkpoint inhibitor treatment effect showed better success in higher expressers in some studies, but also no association in several other studies.<xref ref-type="bibr" rid="article-58888.r33">[33]</xref> Consequently, although response and survival can correlate with PD-L1 expression, alternative methods are needed to stratify which specific patients are most likely to benefit.<xref ref-type="bibr" rid="article-58888.r34">[34]</xref></p>
        <p>The FDA recently changed the pembrolizumab NSCLC monotherapy approval label to include PD-L1 expressers greater than 1% (from greater than 50%). However, without adequate head-to-head studies, pembrolizumab may not provide optimal patient outcomes compared to other approved treatment options in patients with PD-L1 expression between 1 and 49%.<xref ref-type="bibr" rid="article-58888.r26">[26]</xref> Until better biomarkers and additional clinical trial data become available, it is unclear if the original label or the updated label is a better treatment regimen for these patients.</p>
        <p>With the rapid developmental pace in the field of molecular therapeutics for lung cancer, treatment decisions are becoming more personalized and sophisticated. Therefore it will be of great importance to have support systems to help thoracic oncologists stay up-to-date.<xref ref-type="bibr" rid="article-58888.r35">[35]</xref>&#x000a0;Beyond thoracic oncologists, it is also vital for other interprofessional healthcare team members (nurses, pharmacists, and other physicians) to keep up with all the newest developments. The pharmacist must carefully check the patient's medication record and alert the other members of the team (nursing, clinicians) regarding the signs and symptoms of adverse events from pembrolizumab. Armed with this knowledge, nursing can do a much better job of monitoring the patient and assessing treatment progress. With proper support and education, drugs such as pembrolizumab can be used safely and appropriately to maximize patient outcomes, but it will require an interprofessional effort on the part of the healthcare team. [Level 5]</p>
      </sec>
      <sec id="article-58888.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=58888&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=58888">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/58888/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=58888">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-58888.s11">
        <title>References</title>
        <ref id="article-58888.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schachter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ribas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Arance</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grob</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Mortier</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Daud</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carlino</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>McNeil</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lotem</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Larkin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lorigan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Neyns</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Blank</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Petrella</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Hamid</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ebbinghaus</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Robert</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).</article-title>
            <source>Lancet</source>
            <year>2017</year>
            <month>Oct</month>
            <day>21</day>
            <volume>390</volume>
            <issue>10105</issue>
            <fpage>1853</fpage>
            <page-range>1853-1862</page-range>
            <pub-id pub-id-type="pmid">28822576</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamid</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Puzanov</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Dummer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schachter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Daud</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schadendorf</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Blank</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cranmer</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Robert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pavlick</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hodi</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Ascierto</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Salama</surname>
                <given-names>AKS</given-names>
              </name>
              <name>
                <surname>Margolin</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Gangadhar</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Ebbinghaus</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ribas</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.</article-title>
            <source>Eur J Cancer</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>86</volume>
            <fpage>37</fpage>
            <page-range>37-45</page-range>
            <pub-id pub-id-type="pmid">28961465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eggermont</surname>
                <given-names>AMM</given-names>
              </name>
              <name>
                <surname>Blank</surname>
                <given-names>CU</given-names>
              </name>
              <name>
                <surname>Mandala</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Atkinson</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dalle</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haydon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lichinitser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khattak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carlino</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Larkin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Puig</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ascierto</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Rutkowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schadendorf</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Koornstra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hernandez-Aya</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Maio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van den Eertwegh</surname>
                <given-names>AJM</given-names>
              </name>
              <name>
                <surname>Grob</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Gutzmer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jamal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lorigan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Marreaud</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>van Akkooi</surname>
                <given-names>ACJ</given-names>
              </name>
              <name>
                <surname>Suciu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Robert</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>May</month>
            <day>10</day>
            <volume>378</volume>
            <issue>19</issue>
            <fpage>1789</fpage>
            <page-range>1789-1801</page-range>
            <pub-id pub-id-type="pmid">29658430</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gandhi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Abreu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gadgeel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Esteban</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Felip</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>De Angelis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Domine</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Clingan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hochmair</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Bischoff</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Peled</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Grossi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jennens</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Reck</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hui</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Garon</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rubio-Viqueira</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Novello</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kurata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Vida</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Raftopoulos</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pietanza</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Garassino</surname>
                <given-names>MC</given-names>
              </name>
              <collab>KEYNOTE-189 Investigators</collab>
            </person-group>
            <article-title>Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>May</month>
            <day>31</day>
            <volume>378</volume>
            <issue>22</issue>
            <fpage>2078</fpage>
            <page-range>2078-2092</page-range>
            <pub-id pub-id-type="pmid">29658856</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paz-Ares</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Luft</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vicente</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tafreshi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>G&#x000fc;m&#x000fc;&#x0015f;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mazi&#x000e8;res</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hermes</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>&#x000c7;ay &#x0015e;enler</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cs&#x00151;szi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>F&#x000fc;l&#x000f6;p</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Cid</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sugawara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Novello</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Halmos</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lubiniecki</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Piperdi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kowalski</surname>
                <given-names>DM</given-names>
              </name>
              <collab>KEYNOTE-407 Investigators</collab>
            </person-group>
            <article-title>Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Nov</month>
            <day>22</day>
            <volume>379</volume>
            <issue>21</issue>
            <fpage>2040</fpage>
            <page-range>2040-2051</page-range>
            <pub-id pub-id-type="pmid">30280635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reck</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Abreu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Hui</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cs&#x00151;szi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>F&#x000fc;l&#x000f6;p</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gottfried</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peled</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tafreshi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cuffe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hotta</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vandormael</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Riccio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pietanza</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Brahmer</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.</article-title>
            <source>J Clin Oncol</source>
            <year>2019</year>
            <month>Mar</month>
            <day>01</day>
            <volume>37</volume>
            <issue>7</issue>
            <fpage>537</fpage>
            <page-range>537-546</page-range>
            <pub-id pub-id-type="pmid">30620668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herbst</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Baas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Felip</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez-Gracia</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Molina</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Arvis</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Majem</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fidler</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>de Castro</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Garrido</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lubiniecki</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Shentu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Im</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dolled-Filhart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garon</surname>
                <given-names>EB</given-names>
              </name>
            </person-group>
            <article-title>Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.</article-title>
            <source>Lancet</source>
            <year>2016</year>
            <month>Apr</month>
            <day>09</day>
            <volume>387</volume>
            <issue>10027</issue>
            <fpage>1540</fpage>
            <page-range>1540-1550</page-range>
            <pub-id pub-id-type="pmid">26712084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nan</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Gold</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Immunotherapeutic Approaches to the Management of Head and Neck Cancer.</article-title>
            <source>Oncology (Williston Park)</source>
            <year>2018</year>
            <month>Dec</month>
            <day>17</day>
            <volume>32</volume>
            <issue>12</issue>
            <fpage>617</fpage>
            <page-range>617-9, 625-6</page-range>
            <pub-id pub-id-type="pmid">30632130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mehra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Seiwert</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gluck</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Eder</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Burtness</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tahara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Keam</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Muro</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Geva</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Aurora-Garg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pathiraja</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chow</surname>
                <given-names>LQM</given-names>
              </name>
              <name>
                <surname>Haddad</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.</article-title>
            <source>Br J Cancer</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>119</volume>
            <issue>2</issue>
            <fpage>153</fpage>
            <page-range>153-159</page-range>
            <pub-id pub-id-type="pmid">29955135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rini</surname>
                <given-names>BI</given-names>
              </name>
              <name>
                <surname>Plimack</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Stus</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gafanov</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nosov</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pouliot</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Alekseev</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Souli&#x000e8;res</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Melichar</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vynnychenko</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kryzhanivska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bondarenko</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Azevedo</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Borchiellini</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Szczylik</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Markus</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McDermott</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Bedke</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tartas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Tamada</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shou</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Perini</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Atkins</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Powles</surname>
                <given-names>T</given-names>
              </name>
              <collab>KEYNOTE-426 Investigators</collab>
            </person-group>
            <article-title>Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Mar</month>
            <day>21</day>
            <volume>380</volume>
            <issue>12</issue>
            <fpage>1116</fpage>
            <page-range>1116-1127</page-range>
            <pub-id pub-id-type="pmid">30779529</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fradet</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bellmunt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vaughn</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Fong</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vogelzang</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Climent</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Petrylak</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Choueiri</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Necchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gerritsen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Gurney</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Culine</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sternberg</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Nam</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Frenkl</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Perini</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>de Wit</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bajorin</surname>
                <given-names>DF</given-names>
              </name>
            </person-group>
            <article-title>Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of &#x0003e;2 years of follow-up.</article-title>
            <source>Ann Oncol</source>
            <year>2019</year>
            <month>Jun</month>
            <day>01</day>
            <volume>30</volume>
            <issue>6</issue>
            <fpage>970</fpage>
            <page-range>970-976</page-range>
            <pub-id pub-id-type="pmid">31050707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zinzani</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Fanale</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Armand</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Brice</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Radford</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ribrag</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Molin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vassilakopoulos</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Tomita</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>von Tresckow</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Shipp</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ricart</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Balakumaran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moskowitz</surname>
                <given-names>CH</given-names>
              </name>
              <collab>KEYNOTE-087</collab>
            </person-group>
            <article-title>Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.</article-title>
            <source>J Clin Oncol</source>
            <year>2017</year>
            <month>Jul</month>
            <day>01</day>
            <volume>35</volume>
            <issue>19</issue>
            <fpage>2125</fpage>
            <page-range>2125-2132</page-range>
            <pub-id pub-id-type="pmid">28441111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomassetti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dandapani</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma.</article-title>
            <source>Ther Adv Hematol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>2040620719841591</fpage>
            <pub-id pub-id-type="pmid">31040936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suzman</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ning</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Maher</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Fernandes</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Karuri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sridhara</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schroeder</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McKee</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Pazdur</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Beaver</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.</article-title>
            <source>Oncologist</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>563</fpage>
            <page-range>563-569</page-range>
            <pub-id pub-id-type="pmid">30541754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oliveira</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Bretes</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Furtado</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer.</article-title>
            <source>Front Oncol</source>
            <year>2019</year>
            <volume>9</volume>
            <fpage>396</fpage>
            <pub-id pub-id-type="pmid">31139574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fuchs</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Doi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jang</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Muro</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Satoh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Machado</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Jalal</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Metges</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Garrido</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Golan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mandala</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wainberg</surname>
                <given-names>ZA</given-names>
              </name>
              <name>
                <surname>Catenacci</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Ohtsu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shitara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Geva</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bleeker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Ku</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Philip</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Enzinger</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Bang</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Levitan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rosales</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dalal</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.</article-title>
            <source>JAMA Oncol</source>
            <year>2018</year>
            <month>May</month>
            <day>10</day>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>e180013</fpage>
            <pub-id pub-id-type="pmid">29543932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chung</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Ros</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Delord</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Perets</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Italiano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shapira-Frommer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Manzuk</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Piha-Paul</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zeigenfuss</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pruitt</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Leary</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.</article-title>
            <source>J Clin Oncol</source>
            <year>2019</year>
            <month>Jun</month>
            <day>10</day>
            <volume>37</volume>
            <issue>17</issue>
            <fpage>1470</fpage>
            <page-range>1470-1478</page-range>
            <pub-id pub-id-type="pmid">30943124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhu</surname>
                <given-names>AX</given-names>
              </name>
              <name>
                <surname>Finn</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Edeline</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cattan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ogasawara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Verslype</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zagonel</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fartoux</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vogel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sarker</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Verset</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Knox</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Daniele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Webber</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Ebbinghaus</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Kudo</surname>
                <given-names>M</given-names>
              </name>
              <collab>KEYNOTE-224 investigators</collab>
            </person-group>
            <article-title>Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>19</volume>
            <issue>7</issue>
            <fpage>940</fpage>
            <page-range>940-952</page-range>
            <pub-id pub-id-type="pmid">29875066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nghiem</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lipson</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Sharfman</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Kudchadkar</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Brohl</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Friedlander</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Daud</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kluger</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Boulmay</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Riker</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Burgess</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Hanks</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Olencki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Margolin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lundgren</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Soni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ramchurren</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Church</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Shinohara</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Salim</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Taube</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bird</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fling</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Homet Moreno</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sharon</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cheever</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Topalian</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.</article-title>
            <source>J Clin Oncol</source>
            <year>2019</year>
            <month>Mar</month>
            <day>20</day>
            <volume>37</volume>
            <issue>9</issue>
            <fpage>693</fpage>
            <page-range>693-702</page-range>
            <pub-id pub-id-type="pmid">30726175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Passiglia</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Novello</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Immunotherapy in first line for extensive-stage small-cell lung cancer: another piece is going to fill the puzzle?</article-title>
            <source>Ann Transl Med</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>6</volume>
            <issue>Suppl 2</issue>
            <fpage>S120</fpage>
            <pub-id pub-id-type="pmid">30740441</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Francisco</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Sage</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Sharpe</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>The PD-1 pathway in tolerance and autoimmunity.</article-title>
            <source>Immunol Rev</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>236</volume>
            <fpage>219</fpage>
            <page-range>219-42</page-range>
            <pub-id pub-id-type="pmid">20636820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zou</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Inhibitory B7-family molecules in the tumour microenvironment.</article-title>
            <source>Nat Rev Immunol</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>467</fpage>
            <page-range>467-77</page-range>
            <pub-id pub-id-type="pmid">18500231</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pardoll</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>The blockade of immune checkpoints in cancer immunotherapy.</article-title>
            <source>Nat Rev Cancer</source>
            <year>2012</year>
            <month>Mar</month>
            <day>22</day>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>252</fpage>
            <page-range>252-64</page-range>
            <pub-id pub-id-type="pmid">22437870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ribas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Puzanov</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Dummer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schadendorf</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hamid</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Robert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hodi</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Schachter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pavlick</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Cranmer</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Blank</surname>
                <given-names>CU</given-names>
              </name>
              <name>
                <surname>O'Day</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Ascierto</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Salama</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Margolin</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Loquai</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Eigentler</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Gangadhar</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Carlino</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Agarwala</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Moschos</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Sosman</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Goldinger</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Shapira-Frommer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kirkwood</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Wolchok</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Eggermont</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>XN</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zernhelt</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Lis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ebbinghaus</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Daud</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>16</volume>
            <issue>8</issue>
            <fpage>908</fpage>
            <page-range>908-18</page-range>
            <pub-id pub-id-type="pmid">26115796</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freshwater</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kondic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ahamadi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>de Greef</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>de Alwis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of dosing strategy for pembrolizumab for oncology indications.</article-title>
            <source>J Immunother Cancer</source>
            <year>2017</year>
            <volume>5</volume>
            <fpage>43</fpage>
            <pub-id pub-id-type="pmid">28515943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mok</surname>
                <given-names>TSK</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Kudaba</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kowalski</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Turna</surname>
                <given-names>HZ</given-names>
              </name>
              <name>
                <surname>Castro</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Srimuninnimit</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Laktionov</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Bondarenko</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kubota</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lubiniecki</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kush</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lopes</surname>
                <given-names>G</given-names>
              </name>
              <collab>KEYNOTE-042 Investigators</collab>
            </person-group>
            <article-title>Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.</article-title>
            <source>Lancet</source>
            <year>2019</year>
            <month>May</month>
            <day>04</day>
            <volume>393</volume>
            <issue>10183</issue>
            <fpage>1819</fpage>
            <page-range>1819-1830</page-range>
            <pub-id pub-id-type="pmid">30955977</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boyiadzis</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Kirkwood</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Pritchard</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Azad</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Gulley</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.</article-title>
            <source>J Immunother Cancer</source>
            <year>2018</year>
            <month>May</month>
            <day>14</day>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <pub-id pub-id-type="pmid">29754585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Puzanov</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Diab</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abdallah</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bingham</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Brogdon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dadu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hamad</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lacouture</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>LeBoeuf</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Lenihan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Onofrei</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shannon</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Silk</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Skondra</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Suarez-Almazor</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wiley</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Ernstoff</surname>
                <given-names>MS</given-names>
              </name>
              <collab>Society for Immunotherapy of Cancer Toxicity Management Working Group</collab>
            </person-group>
            <article-title>Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.</article-title>
            <source>J Immunother Cancer</source>
            <year>2017</year>
            <month>Nov</month>
            <day>21</day>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>95</fpage>
            <pub-id pub-id-type="pmid">29162153</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walker</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Kroumpouzos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Weinstock</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous tumors in pregnancy.</article-title>
            <source>Clin Dermatol</source>
            <year>2016</year>
            <season>May-Jun</season>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>359</fpage>
            <page-range>359-67</page-range>
            <pub-id pub-id-type="pmid">27265074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Longoria</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Tewari</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>12</volume>
            <issue>10</issue>
            <fpage>1247</fpage>
            <page-range>1247-53</page-range>
            <pub-id pub-id-type="pmid">27485741</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maleki Vareki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Garrig&#x000f3;s</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Duran</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Biomarkers of response to PD-1/PD-L1 inhibition.</article-title>
            <source>Crit Rev Oncol Hematol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>116</volume>
            <fpage>116</fpage>
            <page-range>116-124</page-range>
            <pub-id pub-id-type="pmid">28693793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nduom</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yaghi</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Gabrusiewicz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ling</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ivan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JQ</given-names>
              </name>
              <name>
                <surname>Burks</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Fuller</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Calin</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Conrad</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Creasy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ritthipichai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Radvanyi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Heimberger</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>PD-L1 expression and prognostic impact in glioblastoma.</article-title>
            <source>Neuro Oncol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>195</fpage>
            <page-range>195-205</page-range>
            <pub-id pub-id-type="pmid">26323609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brody</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ballas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Siddiqui</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Barker</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Midha</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.</article-title>
            <source>Lung Cancer</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>112</volume>
            <fpage>200</fpage>
            <page-range>200-215</page-range>
            <pub-id pub-id-type="pmid">29191596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flynn</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>O'Hara</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Gandhi</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART).</article-title>
            <source>Transl Lung Cancer Res</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>159</fpage>
            <page-range>159-168</page-range>
            <pub-id pub-id-type="pmid">28529898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58888.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>R&#x000e9;v&#x000e9;sz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Engelhardt</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Tamminga</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Schramel</surname>
                <given-names>FMNH</given-names>
              </name>
              <name>
                <surname>Onwuteaka-Philipsen</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>van de Garde</surname>
                <given-names>EMW</given-names>
              </name>
              <name>
                <surname>Steyerberg</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>de Vet</surname>
                <given-names>HCW</given-names>
              </name>
              <name>
                <surname>Coup&#x000e9;</surname>
                <given-names>VMH</given-names>
              </name>
            </person-group>
            <article-title>Needs with Regard to Decision Support Systems for Treating Patients with Incurable Non-small Cell Lung Cancer.</article-title>
            <source>J Cancer Educ</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>35</volume>
            <issue>2</issue>
            <fpage>345</fpage>
            <page-range>345-351</page-range>
            <pub-id pub-id-type="pmid">30685832</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
